^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
micvotabart pelidotin (PYX-201)
i
Other names: PYX-201, PYX201, PYX 201
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Pfizer, Pyxis Oncology
Drug class:
Microtubule inhibitor, Extra-domain B of fibronectin-targeted antibody-drug conjugate
Related drugs:
4ms
Study of PYX-201 in Solid Tumors (clinicaltrials.gov)
P1, N=80, Recruiting, Pyxis Oncology, Inc | N=45 --> 80 | Trial primary completion date: May 2024 --> Jul 2026
Enrollment change • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
micvotabart pelidotin (PYX-201)
Share via
